超声电导靶向导入头孢菌素治疗慢性前列腺炎80例的临床分析  

Clinical Analysis of Cephalosporin Conducted by Ultrasonic Conductometric Prostate Therapeutic Apparatus in the Treatment of Eighty Cases of Chronic Prostatitis

作　　者：宫满成[1] 董文静[2] 丘少鹏[3] 邓德成[1] 袁润强[1] 

机构地区：[1]中山市人民医院泌尿外科,广东中山528403 [2]中山市人民医院肿瘤内科,广东中山528403 [3]中山大学附属第一医院泌尿外科,广东广州510080

出　　处：《现代生物医学进展》2016年第5期864-867,共4页Progress in Modern Biomedicine

摘　　要：目的：观察超声电导前列腺治疗仪经直肠导入二代头孢菌素（头孢呋辛）联合口服α受体阻滞剂（坦索罗辛）治疗Ⅲ型慢性前列腺炎的临床疗效。方法：将160例Ⅲ型慢性前列腺炎患者随机分为口服坦索罗辛组（对照组）和经直肠导入注射用头孢呋辛钠联合口服坦索罗辛组（治疗组）。对照组每天服药一次,共治疗6周。治疗组每天治疗1次,10天为一个疗程,两个疗程之间间隔7-10天,共3个疗程。采用慢性前列腺炎症状指数（NIH-CPSI）作为评分体系,分别观察和比较两组患者治疗前后的NIH-CPSI总分、疼痛评分、排尿评分和生活质量评分。结果：治疗组和对照组的总有效率分别为90.00%和68.8%,治疗组显著高于对照组（P〈0.05）。治疗后,两组患者的NIH-CPSI总评分、疼痛积分、排尿积分及生活质量评分都较治疗前显著改善（P〈0.05）,且治疗组的症状改善较对照组更加明显,其各项评分均显著低于对照组（P〈0.05）。结论：采用超声电导前列腺治疗仪经直肠导入二代头孢菌素（头孢呋辛）联合口服α受体阻滞剂（坦索罗辛）可更加有效地治疗前列腺炎,改善患者的临床症状,并提高患者的生活质量,且毒副作用小,值得临床推广。Objective： To observe the clinical efficacy of second generation cephalosporin（Cefuroxime） combined with alpha blockers（Tamsulosin） conducted by ultrasonic conductometric prostate therapeutic apparatus in the treatment of chronic prostatitis typeⅢ. Methods： One hundred and sixty chronic prostatitis type Ⅲ patients were randomized into two groups： the traditional oral drug Tamsulosin treatment group（control group） and the combination of Tamsulosin and Cefuroxime Sodi delivered by the ultrasonic conductometric prostate therapeutic apparatus group（observation group）. The patients of control group took medicine once per day, a total treatment of six weeks. Patients of treatment group received therapy once per day, 10 days for a period of treatment. Interval between two courses of treatment was 7 - 10 days, the patients received a total of three courses. We used the chronic inflammatory prostate index（NIH-CPSI） as the scoring system, and mainly observed and compared the NIH-CPSI total score, urinate pain score, micturition score and quality of life score before and after treatment between two groups. Results： The clinical efficacy of treatment group and control group were 90.00% and 68.8% respectively, which was much higher in the treatment group than that of the control group（P〈0.05）. After treatment, the NIH-CPSI total score, urinate pain score, micturition score and quality of life score of both treatment group and control group were significantly better than those before treatment（P〈0.05）. Moreover, the symptoms of treatment group improved more obviously than the control group, and all of the scores were significantly lower than those of the control group（P〈0.05）. Conclusions： Using the ultrasonic conductometric prostate therapeutic apparatus transrectal imported the second generation cephalosporin（Cefuroxime） combined with alpha blockers（Tamsulosin） could more effectively treat the prostatitis, and improve the patient＇s clinical symptoms, also improve

关 键 词：Ⅲ型慢性前列腺炎 超声电导前列腺治疗仪 经直肠透药 

分 类 号：R697.33[医药卫生—泌尿科学]